8-K: Shuttle Pharmaceuticals Amends Agreement with Alto Opportunity Master Fund, Waiving Future Investment Rights

Shuttle Pharmaceuticals Holdings, Inc. amended its Securities Purchase Agreement with Alto Opportunity Master Fund, waiving Alto's right to future investments in exchange for a $75,000 payment.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. entered into an amendment agreement with Alto Opportunity Master Fund, SPC on February 26, 2025.
• The amendment modifies the terms of the Securities Purchase Agreement originally dated January 11, 2023, and amended several times since.
• Under the agreement, Shuttle Pharmaceuticals will pay $75,000 to Alto Opportunity Master Fund.
• In exchange, Alto Opportunity Master Fund waives its right to purchase up to $10 million in Additional Notes and Additional Warrants.
• Alto Opportunity Master Fund also grants a one-time waiver of its right to participate in Shuttle Pharmaceuticals' contemplated registered securities offering, as disclosed in the Form S-1 filed on February 13, 2025.
• The company filed a Form 8-K with the SEC to disclose the amendment.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company incurs a $75,000 payment, it gains flexibility in its financing strategy by eliminating potential future obligations and securing a waiver for its securities offering.

Positives

• Shuttle Pharmaceuticals eliminates the potential obligation to issue up to $10 million in Additional Notes and Additional Warrants.
• The company gains more flexibility in its contemplated registered securities offering by obtaining a waiver from Alto Opportunity Master Fund.

Negatives

• Shuttle Pharmaceuticals incurs a $75,000 payment to Alto Opportunity Master Fund.

Risks

• The company's financial condition may be impacted by the $75,000 payment.
• The company's contemplated registered securities offering is subject to market conditions and regulatory approval.

Future Outlook

The company intends to proceed with its contemplated registered securities offering, as disclosed in its Form S-1 filing.

Management Comments

• The document includes a signature from Anatoly Dritschilo, Chief Executive Officer of Shuttle Pharmaceuticals Holdings, Inc.

Industry Context

Companies often renegotiate financing agreements to optimize their capital structure and secure more favorable terms, especially when planning a securities offering.

Comparison to Industry Standards

• It is common for companies to amend existing agreements with investors to adjust investment rights and obligations.
• The specific terms of the amendment, such as the $75,000 payment and the waiver of future investment rights, would need to be compared to similar transactions in the biotechnology or pharmaceutical industry to assess their relative favorability.
• Comparable companies and projects would need to be identified to benchmark the terms of this agreement.

Stakeholder Impact

• Shareholders may be impacted by the company's financing strategy and the terms of the amendment agreement.
• The company's ability to raise capital through its securities offering could affect its future operations and growth prospects.

Next Steps

• Shuttle Pharmaceuticals will pay $75,000 to Alto Opportunity Master Fund within 2 trading days.
• The company will proceed with its contemplated registered securities offering, aiming to consummate the Subsequent Placement no later than March 31, 2025.

Key Dates